CLENE INC. news, videos and press releases
For more news please use our advanced search feature.
CLENE INC. - More news...
CLENE INC. - More news...
- Clene to Present at the Emerging Growth Conference
- Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)
- Clene to Present at Upcoming May Conferences
- Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights
- Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
- Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®
- Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights
- Clene to Present at the 36th Annual ROTH Conference
- Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024
- Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs
- Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8® Treatment in VISIONARY-MS Trial Long-Term Open Label Extension
- Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension
- Clene Provides Update on ALS Clinical Development Meeting With FDA
- Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases
- Clene Reports Third Quarter 2023 Financial Results and Operating Highlights
- National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS
- Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action
- Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference
- Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls
- Clene to Present at Upcoming September Conferences
- Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up
- Clene Reports Second Quarter 2023 Financial Results and Operating Highlights
- Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference
- Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET’s eClinicalMedicine
- Clene Welcomes New Shareholder Base and Announces Closing of Underwritten Public Offering of $40 Million
- Clene Announces Pricing of $40 Million Public Offering
- Clene Announces Launch of Proposed Public Offering
- Clene’s CNM-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) levels in the HEALEY ALS Platform Trial
- Clene to Participate in the Maxim Group Virtual Healthcare Conference
- Clene Awarded Grant From National Multiple Sclerosis Society to Advance Development of CNM-Au8® in Non-Active Progressive Multiple Sclerosis